Methods and Design of the MYLUNG Consortium for mNSCLC

Nicholas J. Robert, MD, an oncologist at US Oncology Network and the vice president of Medical Affairs, Ontada, discusses the poster he presented at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO).

In the presentation, Robert discussed the MYLUNG Consortium, which examined patient factors associated with the rates of biomarker testing in patients with metastatic non–small cell lung cancer (mNSCLC). The goal of the consortium is to identify the trends in testing rates to discover ways they could be advanced, specifically in this mNSCLC patient population.

Transcription:

0:08 | The poster looked at the indicators of who had biomarkers done in the setting of metastatic non-small cell lung cancer. We looked at 3500 patients over a 2-year period, starting in March 2018-April 2020. We looked to see if patients were having biomarkers which are important to evaluate what treatment options a patient has with metastatic non-small cell lung cancer.

0:36 | We reported that if you did the whole panel, which were 5 biomarkers, this occurred about 46% of the time. It should be happening around 90% plus, so 46% is not a great number. The good news was that this part of the MYLUNG Consortium is so-called protocol 1, and we are doing protocol 2, which is looking at patients in a prospective fashion. Then protocol 3 will be interventions.

1:09 | With that information, what we then did was [look at] the indicators, and the poster goes over a number of variables like age, gender, ECOG, performance status, stage at presentation, but we also looked at other variables which came out to be meaningful in a multivariate predictive model. They were [that] African Americans were less tested than non-African Americans. The histology squamous was less tested, and that makes a lot of sense, because the biomarker really started with adenocarcinoma, which is a non-squamous histology.